Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...

Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...

Background A 31-year-old woman presented 12 months after discontinuing the oral contraceptive pill with progressive headache to her primary-care physician. She had previously presented with irregular ...

This prospective, cross-sectional, and comparative study included 30 patients with acromegaly (study group) and 30 healthy subjects (control group). The subfoveal choroidal thickness (SFCT), foveal ...

Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...

Acromegaly is one of those diseases that immediately caught our attention when we first heard about it in medical school. We stared at the textbook pictures of big hands and coarse faces—maybe a very ...

Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly are more likely to have hypertension, diabetes and other comorbidities than healthy ...

When Ray Kohn started feeling pain in his knees and elbows in 2015, he attributed it to his work as a stunt driver and mechanic. But as the years went on, he began to notice his body changing in ...

US FDA accepts Camurus’ resubmission of NDA for Oclaiz for treatment of acromegaly: Lund, Sweden Monday, January 12, 2026, 15:00 Hrs [IST] Camurus, an international, science-led ...

A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...